Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress
Caris Life Sciences Showcases Innovative Cancer Research at ESMO 2025 Congress
Caris Life Sciences, a leader in patient-centric precision medicine and AI TechBio innovation, will be presenting six pivotal studies at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17 to 21. This event will serve as a platform for Caris to demonstrate the transformative capabilities of multiomics—a comprehensive scientific method merging data across various biological levels to develop a holistic understanding of diseases.
The studies being introduced encompass a spectrum of nine different tumor types, emphasizing how integrated profiling and biomarker discovery can significantly enhance treatment decisions and, ultimately, patient outcomes. Each presented study has been performed in collaboration with over 25 prestigious cancer centers from the United States, Europe, and Japan, all members of the Caris Precision Oncology Alliance (POA).
The research will be exhibited in multiple formats including one oral presentation designated as a 'Proffered Paper', a mini-oral presentation, and four poster presentations. These studies underline Caris's expertise in utilizing advanced sequencing methods like whole exome sequencing (WES) and whole transcriptome sequencing (WTS), along with immunohistochemistry (IHC) and real-world clinico-genomic data to extract actionable insights.
Tumor types represented in the studies include colorectal, gastric, breast, pancreatic, head and neck, prostate, urothelial, renal, and biliary tract cancers. The studies aim to refine cancer subtyping and treatment decisions by integrating real-world data alongside advanced sequencing, ultimately striving to improve patient outcomes across diverse cancer types.
Dr. Milan Radovich, Senior Vice President and Chief Scientific Officer at Caris, highlighted the importance of the ESMO platform for disseminating their findings: "By integrating real-world data, advanced sequencing, and biomarker discovery, we're refining cancer subtyping and treatment decisions to improve patient outcomes across numerous cancer types. ESMO provides an international stage to share these insights and accelerate the future of personalized cancer care."
Breakdown of Presentations
The presentations will cover the following:
- - Oral 'Proffered Paper':
- - Mini-Oral Presentation:
- - Poster Presentations:
- Optimizing Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer Through Tailored, Subtype-Specific Treatment Approaches (Presentation Number 795P) on Sunday, Oct 19, 2025.
- Transcriptomic-Based Prediction of Therapeutic Response in Metastatic RAS-Mutant Colorectal Cancer (Presentation Number 829P) on Sunday, Oct 19, 2025.
- NOTCH: A Dynamic Pathway in Head and Neck Squamous Cell Carcinoma (Presentation Number 1409P) on Monday, Oct 20, 2025.
Following the event, full abstracts detailing the presented studies will be accessible on the Caris website. The Caris Precision Oncology Alliance, comprising 97 cancer centers, academic institutions, research consortia, and healthcare systems—including 45 NCI-designated cancer centers—collaborates to enhance standards of care for molecular testing through innovative research centered on predictive and prognostic markers.
About Caris Life Sciences
Caris Life Sciences has established itself as a pioneer in precision medicine, working to develop and commercialize transformative healthcare solutions utilizing comprehensive molecular profiling through methods like whole exome and whole transcriptome sequencing. The company engages advanced AI and machine learning algorithms to analyze the complex molecular nature of diseases, providing a robust platform to create next-generation precision medicine diagnostic solutions for earlier detection, diagnosis, treatment selection, and drug development.
With its headquarters in Irving, Texas, and additional offices located in major cities including Phoenix, New York, Cambridge, Tokyo, and Basel, Caris Life Sciences continues to expand its services in the U.S. and international markets, firmly adhering to its mission of improving human health through precision medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.